Список литературы

1. Алексеева Е.И. Ювенильный идиопатический артрит: клиническая картина, диагностика, лечение. Вопросы современной педиатрии. 2015; 14(1): 78 - 94.

2. Баранов А.А., Алексеева Е.И. Ювенильный артрит: клинические рекомендации для педиатров. Москва: ПедиатрЪ. 2013.

3. Баранов А.А., Алексеева Е.И., Бзарова Т.М. и др. Протокол ведения пациентов с ювенильным артритом. Вопросы современной педиатрии. 2013; 12: 37 - 56.

4. Детская ревматология. Атлас. 2-е издание. Под ред. А.А. Баранова, Е.Й. Алексеевой Москва: ПедиатрЪ. 2015. 348 с.

5. Beukelman T, Patkar NM, Saag KG. et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011; 63: 465 - 82.

6. Cassidy JT. Textbook of pediatric rheumatology. 6th ed. Phila-delphia: Saunders. 2011.

7. Harris JG, Kessler EA, Verbsky JW. Update on the Treatment of Juvenile Idiopathic Arthritis. Curr Allergy Asthma Rep. 2013; 13(4): 337 - 346.

8. Horneff G. Update on biologicals for treatment of juvenile idiopathic arthritis. Expert Opin Biol Ther. 2013; 13(3): 361 - 376.

9. Kingsbury DJ, Bader-Meunier B, Patel G. et al. Safety, effective ness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years. Clin Rheumatol. 2014. Doi: 10.1007/si 0067-014-2498-1.

10. Marzan KAB, Shaham B. Early juvenile idiopathic arthritis. Rheum Dis Clin North Am. 2012; 38: 355 - 72.

11. Otten MH, Anink J, Spronk S. et al. Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons. Ann Rheum Dis. 2013; 72: 1806 - 12. Doi: 10.1136/annrheumdis-2012-201991.

12. Petty RE, Laxer RM, Lindsley CB. et al. Textbook of pediatric rheumatology. 5th edn. Elsevier Saunders, Philadelphia. 2016.

13. Petty R.E., Southwood T.R., Manners P. et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004; 31: 390 - 2.

14. Ungar W. et al. The use of biologic response modifiers in polyarticular course juvenile idiopathic arthriits: a systematic review. Sem Arth Rheum. 2013; 42: 597 - 618.

15. Wallace CA, Giannini EH, Huang B. et al. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011; 63: 929 - 36.

16. Wallace CA, Giannini EH, Spalding SJ. et al. Trial of early ag gressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012; 64: 2012 - 21.

17. Horneff G, Klein A, Oommen PT, Hospach A, Foeldvari I, Feddersen I, Minden K. Update on malignancies in children with juvenile idiopathic arthritis in the German BIKER Registry. Clin Exp Rheumatol. 2016 Sep 8.

18. Windschall D, Horneff G. Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis. Clin Rheumatol. 2016 Dec; 35(12): 2925 - 2931.

19. Constantin T, Foeldvari I, Vojinovic J, Horneff G, Burgos-Vargas R, Nikishina I, Akikusa JD, Avcin T, Chaitow J, Koskova E, Lauwerys BR, Calvo Penades I, Flato B, Gamir ML, Huppertz HI, Jaller Raad JJ, Jarosova K, Anton J, Macku M, Otero Escalante WJ, Rutkowska-Sak L, Trauzeddel R, Velez-Sanchez PJ, Wouters C, Wajdula J, Zang C, Bukowski J, Woodworth D, Vlahos B, Martini A, Ruperto N. Twoyear Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis. J Rheumatol. 2016 Apr; 43(4): 816 - 24. doi: 10.3899/jrheum.150430.

20. van Dijkhuizen EH, Pouw JN, Scheuern A, , Hardt S, Ganser G, , Horneff G, Holzinger D, , Wulffraat NM. Methotrexate intolerance in oral and subcutaneous administration in patients with juvenile idiopathic arthritis: a cross-sectional, observational study. Clin Exp Rheumatol. 2016 Jan-Feb; 34(1): 148 - 54

21. Klotsche J, Niewerth M, Haas JP, Huppertz HI, Zink A, Horneff G, Minden K. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). Ann Rheum Dis. 2016 May; 75(5): 855 - 61. doi: 10.1136/annrheumdis-annrheumdis-2014-206747.